NO20045699L - Bisindolyl-maleimidderivater som kinaseinhibitorer - Google Patents

Bisindolyl-maleimidderivater som kinaseinhibitorer

Info

Publication number
NO20045699L
NO20045699L NO20045699A NO20045699A NO20045699L NO 20045699 L NO20045699 L NO 20045699L NO 20045699 A NO20045699 A NO 20045699A NO 20045699 A NO20045699 A NO 20045699A NO 20045699 L NO20045699 L NO 20045699L
Authority
NO
Norway
Prior art keywords
compounds
kinase inhibitors
kinase
bisindolyl
methods
Prior art date
Application number
NO20045699A
Other languages
English (en)
Norwegian (no)
Inventor
Keith Demarest
Han-Cheng Zhang
Bruce Conway
Hong Ye
Bruce E Maryanoff
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20045699L publication Critical patent/NO20045699L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
NO20045699A 2002-06-05 2004-12-29 Bisindolyl-maleimidderivater som kinaseinhibitorer NO20045699L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38593502P 2002-06-05 2002-06-05
PCT/US2003/017569 WO2003104222A1 (en) 2002-06-05 2003-06-04 Bisindolyl-maleimid derivatives as kinase inhibitors

Publications (1)

Publication Number Publication Date
NO20045699L true NO20045699L (no) 2005-01-28

Family

ID=29736126

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045699A NO20045699L (no) 2002-06-05 2004-12-29 Bisindolyl-maleimidderivater som kinaseinhibitorer

Country Status (14)

Country Link
US (1) US6987110B2 (ko)
EP (1) EP1513830A1 (ko)
JP (1) JP2005531609A (ko)
KR (1) KR20050008787A (ko)
CN (1) CN1671694A (ko)
AU (1) AU2003238874A1 (ko)
BR (1) BR0311821A (ko)
CA (1) CA2488602A1 (ko)
CR (1) CR7606A (ko)
IL (1) IL165515A0 (ko)
MX (1) MXPA04012188A (ko)
NO (1) NO20045699L (ko)
RU (1) RU2004135382A (ko)
WO (1) WO2003104222A1 (ko)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03005140A (es) 2000-12-08 2004-10-15 Johnson & Johnson Compuestos de pirrolina sustituidos con indazolilo como inhibidores de cinasa.
SE0200979D0 (sv) * 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
SE0302546D0 (sv) * 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
AU2003225295A1 (en) * 2002-05-08 2003-11-11 Janssen Pharmaceutica N.V. Substituted pyrroline kinase inhibitors
DE60323749D1 (de) * 2002-06-05 2008-11-06 Janssen Pharmaceutica Nv Substituierte pyrroline als kinase inhibitoren
CA2393720C (en) * 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
AU2002951253A0 (en) * 2002-09-06 2002-09-19 Medvet Science Pty. Ltd. A method of modulating cellular activity
CA2520590A1 (en) * 2003-03-27 2004-11-04 Janssen Pharmaceutica, N.V. Substituted pyrroline kinase inhibitors
EA200600032A1 (ru) 2003-06-13 2006-06-30 Янссен Фармацевтика Н.В. Замещённые производные индазолил (индолил) малеимида в качестве ингибиторов киназ
WO2005083105A2 (en) * 2004-02-26 2005-09-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glycogen synthase kinase 3 beta (gsk3b)
WO2005095983A1 (en) * 2004-03-04 2005-10-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with protein kinase c, gamma (prkcg)
EP1734952A1 (en) * 2004-04-08 2006-12-27 Novartis AG Protein kinase c inhibitors for the treatment of autoimmune diseases and of transplant rejection
WO2006025889A2 (en) * 2004-05-21 2006-03-09 The Texas A & M University System Inhibition of atherosclerosis by diindolylmethane analogs
EP1662259A1 (en) * 2004-11-25 2006-05-31 Cellzome Ag Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
SI1888123T1 (sl) * 2005-06-08 2013-04-30 Janssen Biotech, Inc. Celična terapija za okularno degeneracijo
KR20080023732A (ko) * 2005-07-11 2008-03-14 노파르티스 아게 인돌릴말레이미드 유도체
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
CA2624378A1 (en) * 2005-09-29 2007-04-12 Janssen Pharmaceutica N.V. Macroheterocylic compounds as kinase inhibitors
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20090324610A1 (en) * 2006-04-25 2009-12-31 Kyushu Univeristy, National University Corporation Gene associated with arteriosclerotic disease, and use thereof
US8741643B2 (en) * 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2008063278A (ja) * 2006-09-07 2008-03-21 Fujifilm Finechemicals Co Ltd １−ピリジン−４−イル−インドール類の製造方法
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
CN101952415B (zh) 2007-07-31 2017-06-27 生命扫描有限公司 人胚胎干细胞的分化
CN107574142B (zh) * 2007-11-27 2021-07-06 生命扫描有限公司 人胚胎干细胞的分化
FR2927075A1 (fr) * 2008-02-04 2009-08-07 Centre Nat Rech Scient Molecules comprenant un squelette bis-(heteroaryl)maleimide, et leur utilisation dans l'inhibition d'enzymes
CN105886459A (zh) 2008-02-21 2016-08-24 詹森生物科技公司 用于细胞粘附、培养和分离的方法、表面改性培养板和组合物
US8623648B2 (en) * 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
US20090291982A1 (en) * 2008-05-22 2009-11-26 Astrazeneca Ab New Substituted Oxindole Derivative 352
CA2729121C (en) 2008-06-30 2019-04-09 Centocor Ortho Biotech Inc. Differentiation of pluripotent stem cells
WO2010002785A1 (en) * 2008-06-30 2010-01-07 Centocor Ortho Biotech Inc. Differentiation of pluripotent stem cells
US20100028307A1 (en) * 2008-07-31 2010-02-04 O'neil John J Pluripotent stem cell differentiation
JP2012507289A (ja) 2008-10-31 2012-03-29 ヤンセン バイオテツク，インコーポレーテツド ヒト胚性幹細胞の膵内分泌系への分化
AU2009308967C1 (en) * 2008-10-31 2017-04-20 Janssen Biotech, Inc. Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
CN102257132B (zh) * 2008-11-20 2014-09-03 森托科尔奥索生物科技公司 用于在平面基底上进行细胞附着和培养的方法和组合物
MX2011005288A (es) 2008-11-20 2011-06-01 Centocor Ortho Biotech Inc Celulas madre pluripotentes en microportadores.
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
ES2693088T3 (es) 2009-07-20 2018-12-07 Janssen Biotech, Inc. Diferenciación de células madre embriónicas humanas
JP6219568B2 (ja) 2009-07-20 2017-10-25 ヤンセン バイオテツク，インコーポレーテツド ヒト胚性幹細胞の分化
WO2011011349A2 (en) 2009-07-20 2011-01-27 Centocor Ortho Biotech Inc. Differentiation of human embryonic stem cells
CN107058389A (zh) * 2009-10-29 2017-08-18 詹森生物科技公司 多能干细胞
RU2586506C2 (ru) * 2009-12-23 2016-06-10 Янссен Байотек, Инк. Дифференцировка человеческих эмбриональных стволовых клеток
BR112012017761A2 (pt) * 2009-12-23 2015-09-15 Centocor Ortho Biotech Inc diferenciação das células-tronco embrionárias humanas
US9969981B2 (en) 2010-03-01 2018-05-15 Janssen Biotech, Inc. Methods for purifying cells derived from pluripotent stem cells
MX351515B (es) 2010-05-12 2017-10-17 Janssen Biotech Inc Diferenciacion de celulas madre embrionarias humanas.
RU2599420C2 (ru) 2010-08-31 2016-10-10 Янссен Байотек, Инк. Дифференцирование плюрипотентных стволовых клеток
ES2658146T3 (es) 2010-08-31 2018-03-08 Janssen Biotech, Inc. Diferenciación de células madre embrionarias humanas
BR112013004616A2 (pt) 2010-08-31 2016-07-05 Janssen Biotech Inc diferenciação das células tronco embrionárias humanas
ES2387359B1 (es) * 2011-02-25 2013-08-01 Consejo Superior De Investigaciones Científicas (Csic) Inhibidores de GSK-3 útiles en enfermedades neurodegenerativas, inflamatorias, cáncer, diabetes y en procesos regenerativos
KR102090751B1 (ko) 2011-12-22 2020-03-19 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 단일 인슐린 호르몬 양성 세포로의 분화
WO2013134378A1 (en) 2012-03-07 2013-09-12 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
DK3450542T3 (da) 2012-06-08 2021-11-01 Janssen Biotech Inc Differentiering af humane embryonale stamceller til endokrine pancreatiske celler
SG11201505112SA (en) 2012-12-31 2015-07-30 Janssen Biotech Inc Differentiation of human embryonic stem cells into pancreatic endocrine cells using hb9 regulators
RU2018116647A (ru) 2012-12-31 2018-10-24 Янссен Байотек, Инк. Культивация эмбриональных стволовых клеток человека в воздушно-жидкостной зоне взаимодействия с целью их дифференцировки в панкреатические эндокринные клетки
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
CN105705634A (zh) 2012-12-31 2016-06-22 詹森生物科技公司 用于分化成胰腺内分泌细胞的人多能细胞的悬浮和群集
RU2694311C2 (ru) 2014-05-16 2019-07-11 Янссен Байотек, Инк. Применение малых молекул для увеличения экспрессии mafa в панкреатических эндокринных клетках
MA45479A (fr) 2016-04-14 2019-02-20 Janssen Biotech Inc Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
CN109535158B (zh) * 2016-04-26 2021-04-23 浙江工业大学 一种双芳基马来酰亚胺类化合物及其药学上可接受的盐及其制备方法和应用
AU2020218366A1 (en) 2019-02-08 2021-09-16 Frequency Therapeutics, Inc. Valproic acid compounds and Wnt agonists for treating ear disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK278989B6 (sk) 1988-02-10 1998-05-06 F. Hoffmann-La Roche Ag Substituované pyroly, ich použitie na výrobu lieči
GB8904161D0 (en) 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
DK0817627T3 (da) * 1993-12-23 2005-06-06 Lilly Co Eli Inhibitorer af proteinkinase C
CA2249205A1 (en) 1996-03-20 1997-09-25 Eli Lilly And Company Synthesis of indolylmaleimides
SE9603283D0 (sv) * 1996-09-10 1996-09-10 Astra Ab New compounds
EP1057484A4 (en) * 1998-02-23 2002-11-20 Sagami Chem Res INHIBITORS OF CELL DEATH
KR20010085305A (ko) 1998-07-30 2001-09-07 미즈노 마사루 이치환된 말레이미드 화합물 및 그의 의약 용도
ES2234300T3 (es) 1998-10-08 2005-06-16 Smithkline Beecham Plc 3-(3-cloro-4-hidroxifenilamino)-4-(2-nitrofenil)-1h-pirrol-2,5-diona como inhibidor de glucogeno cinasa-3 (gsk-3)sintetasa.
CZ2003555A3 (en) 2000-07-27 2004-03-17 F. Hoffmann-La Roche Ag 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta
EP1337527B1 (en) 2000-11-07 2009-10-14 Novartis AG Indolylmaleimide derivatives as protein kinase c inhibitors

Also Published As

Publication number Publication date
JP2005531609A (ja) 2005-10-20
WO2003104222A1 (en) 2003-12-18
EP1513830A1 (en) 2005-03-16
US20040059113A1 (en) 2004-03-25
CR7606A (es) 2009-01-16
AU2003238874A1 (en) 2003-12-22
BR0311821A (pt) 2005-04-05
RU2004135382A (ru) 2005-06-27
MXPA04012188A (es) 2005-07-25
KR20050008787A (ko) 2005-01-21
CA2488602A1 (en) 2003-12-18
US6987110B2 (en) 2006-01-17
CN1671694A (zh) 2005-09-21
IL165515A0 (en) 2006-01-15

Similar Documents

Publication Publication Date Title
NO20045699L (no) Bisindolyl-maleimidderivater som kinaseinhibitorer
NO20072115L (no) Farmasoytiske forbindelser
NO20061793L (no) 1,4-disubstituerte isoquinilonderlvater som RAF-kinaseinhibitorer nyttige for behandling av proliferative sykdommer
NO20060145L (no) Substituerte indazolyl (indolyl) maleimidderivater som kinase inhibitorer
NO20064579L (no) Bifenylforbindelser anvendelige som muskariniske receptorantagonister
CA2111461A1 (en) 3-Aminopiperidine Derivatives and Related Nitrogen Containing Heterocycles
NO20062633L (no) Pyrazolderivater som proteinkinasemodulatorer
DE69912581D1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
BR0315405A (pt) Compostos inibidores da integrase tricìclica pré-organizados
MY136959A (en) Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
HK1008525A1 (en) Indole derivative as 5-ht1a antagonist and as inhibitors of serotonine reuptake
NO20050007L (no) 1-Heterosyklylalkyl-3-sulfonylazaindol eller -azaindazolderivater som 5-hydroksytryptamin-6 ligander
HK1071366A1 (en) Compounds which inhibit the release of inflammatory cytokines
NO20075409L (no) Substituerte aminoalkyl- og amidoalkyl-benzopyranderivater
JO2274B1 (en) Derivatives of 1-renesulfinyl-2-aryl-pyrrolidine and piperidine
EA200300062A1 (ru) Производные аминоалкилбензоил-бензофурана или бензотиофена, способ их получения и содержащие их композиции
NO20050270L (no) Nye forbindelser, deres anvendelse og fremstilling
WO2006110173A3 (en) Novel compounds
TW200420292A (en) Benzofuran derivative
AU2003281220A1 (en) N-benzyl-3-phenyl-3-heterocyclyl-propionamide compounds as tachykinin and/ or serotonin reuptake inhibitors
EA200602081A1 (ru) Пиридиновые производные алкилоксиндолов в качестве агентов, активных в отношении рецептора 5-нт7
EA200401099A1 (ru) Производные гетероциклического амида
CY1111560T1 (el) Παραγωγα καρβαζολιου ως λειτουργικα συμπλοκα 5-ητ6
NO20076614L (no) Piperidinderivater
PL1751138T3 (pl) Pochodne indol-2-onu do leczenia chorób centralnego układu nerwowego, chorób układu pokarmowego oraz chorób układu krążenia

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application